Heptares to Present on Structure-Based Drug Design Using G Protein-Coupled Receptors at Inaugural Chemistry & Engineering News Virtual Symposium

LONDON and BOSTON, September 16, 2014 /PRNewswire/ --

Heptares Therapeutics notes that its Chief Scientific Officer, Fiona Marshall, will give a presentation entitled "Structure-based Drug Design for G protein-coupled receptors using StaR^® technology" as part of the inaugural "Advances in Drug Discovery and Development" virtual symposium run by Chemical & Engineering News, a publication of the American Chemical Society. The virtual symposium is on Wednesday, 24 September 2014; Dr Marshall's presentation will take place at 2:00pm Eastern Daylight Time and can be viewed live by clicking here and will be available on http://www.heptares.com afterwards. Registration is required.  

Dr Marshall's presentation will cover the use of Heptares' StaR® technology and broader platform to identify and develop novel molecules addressing all major classes of GPCR (A, B and C). Focus will be given to the discovery of new small molecules and antibodies that have become the basis both of Heptares' advancing drug pipeline for treating serious neurological and other diseases, and of its partnered programmes.

For a full list of events at which Heptares will be present, please visit http://www.heptares.com 

About Heptares Therapeutics 

Heptares creates transformative medicines targeting G protein-coupled receptors (GPCRs), a superfamily of drug receptors linked to a wide range of human diseases. Our proprietary structure-based drug design technology enables us to engineer drugs for highly validated, yet historically undruggable or challenging, GPCRs. Using this approach, we have built an exciting pipeline of new medicines with the potential to transform the treatment of Alzheimer's disease, ADHD, diabetes, schizophrenia, migraine, and other diseases. Our pharmaceutical partners include Cubist, MorphoSys, Takeda, AstraZeneca and MedImmune, and we are backed by Clarus Ventures, MVM Life Science Partners, Novartis Venture Fund, the Stanley Family Foundation and Takeda Ventures. To learn more about Heptares, please visit http://www.heptares.com 

HEPTARES is a registered trademark in the EU, Switzerland, US and Japan;  

StaR is a registered trademark in the EU and Japan. 

Contact Information
Citigate Dewe Rogerson (for Heptares)
Mark Swallow, Chris Gardner
+44(0)20-7282-2948/2995
[email protected]

Heptares Therapeutics Ltd
Malcolm Weir, Chief Executive Officer (UK)
+44(0)1707-358-629
[email protected]

Dan Grau, President (USA)
+1-857-222-4586
[email protected]

SOURCE Heptares Therapeutics

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED